Food and Drug Administration has granted Orphan Drug Designation for BXCL701, an investigational orally-available systemic innate immunity activator with dual mechanisms of action, for the treatment of Acute Myeloid Leukemia
. BXCL701 is designed to activate innate immune cells, specifically macrophages, by inhibiting the dipeptidyl dipeptidases DPP8 and DPP9, a novel mechanism, and exerts immune stimulatory activity through a pro-inflammatory form of programmed cell death known as pyroptosis.
During the poster session dedicated to "Acute Myeloid Leukemia
- Clinical" on June 14th 2019, 17:30PM- 19:00PM, the poster "CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia
" will be presented (Final Abstract Code: PF281).
This brief text provides information about aspects of the four most common subtypes of leukemia: acute myeloid leukemia
, acute lymphoblastic leukemia, chronic myeloid leukemia
, and chronic lymphocytic leukemia.
Prognostic significance of the European Leukemia Net standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia
. J Clin Oncol.
Diagnosis and Treatment of Chronic Myeloid Leukemia
(CML) in 2015.
Health care company Astellas Pharma Inc (TSE:4503) revealed on Monday the availability of the XOSPATA for prescription in the US for the treatment of adult patients with Acute Myeloid Leukemia
(AML), a cancer that impacts the blood and bone marrow and its incidence increases with age.
M2 PHARMA-December 11, 2018-Astellas Pharma Inc unveils XOSPATA for prescription in the US for the treatment of Acute Myeloid Leukemia
Acute myeloid leukemia
(AML) represents a group of diseases that is characterized by the clonal expansion of myeloid blasts in peripheral blood, bone marrow, and other organs and cavities.
This difference is proving to be an Achilles' heel that allows researchers to target cancer stem cells without harming healthy cells: the approach has already proven effective in clinical trials against acute myeloid leukemia
and holds promise for other cancers including breast, pancreatic, and liver.
Objective: To evaluate side effects of Imatinib by patients of chronic myeloid leukemia
and their influence on quality of life.
Bone marrow examination showed 22% blasts, which were strongly myeloperoxidase positive (Figure 2a) and were also CD34+ (Figure 2b) confirming the diagnosis of acute myeloid leukemia
. Conventional cytogenetics revealed t(5:12) and trisomy 21 (Figure 2c); the acute myeloid leukemia
molecular panel (FLT3, CEBPA, NPM1, C-kit, and BCR-ABL) was negative.